NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Repost: dennisdave, this post is nonsense. This board has very knowledgeable investors who actually know the history of Northwest Bio, and the difference between the words invent and develop, and have read the patents and contracts between Northwest Bio and UCLA? Have you?

Do you understand that the process that Dr. Liau invented and patented is not used or patented by Northwest Bio? Do you know why?

Hint: Here’s one of Dr. Liau’s/UCLA’s relevant patents:

Methods for detection and treatment of neural cancers

Patent number: 6558668
Abstract: The invention provides a method for inhibiting proliferation of neural cells. The neural cells can be tumor cells, glial cells, neuronal cells, and cells of the central or peripheral nervous systems. The method comprises contacting a neural cell with a molecule that disrupts the biological activity of a granulin molecule. In one embodiment, the molecule is an antibody directed against a granulin peptide. In other embodiments, the molecule is an antisense nucleotide directed against a granulin nucleic acid molecule, or a vaccine comprising a granulin peptide or a polynucleotide encoding a granulin peptide. The invention additionally provides methods for detecting and treating cancer in a neural tissue using granulin-related molecules. Also provided is a method for identifying differentially expressed gene products that are translated from mRNA species, using antibody-based screening of a cDNA expression library.
 
Type: Grant
Filed: February 28, 2001
Issued: May 6, 2003
Assignee: The Regents of the University of California
Inventor: Linda M. Liau
This application claims benefit of U.S. provisional application No. 60/185,321, filed Feb. 28, 2000, the entire contents of which are incorporated herein by reference. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention pertains. Some of these references are indicated by numbers in parentheses. Citations corresponding to these reference numbers can be found at the end of the specification

A pharmaceutical composition or vaccine can contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated in situ. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Numerous gene delivery techniques are well known in the art, such as those described by Rolland, Crit. Rev. Therap. Drug Carrier Systems 15:143-198, 1998, and references cited therein. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope.

When DCs are pulsed with a soluble antigen, including human tumor antigen or tissue specific antigens with an adjuvant such as BCG, enhancement of MHC-class I presentation occurs. Therefore, the presence of an adjuvant such as BCG typically increases DC soluble tumor antigen processing in the MHC-class I compartment and correspondingly, activates a higher percentage of CD8+ T cells when compared to individuals administered the antigen alone.